Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 2
2016 1
2018 1
2019 3
2020 2
2021 3
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Váraljai R, et al. Nat Cancer. 2023 Sep;4(9):1292-1308. doi: 10.1038/s43018-023-00610-2. Epub 2023 Jul 31. Nat Cancer. 2023. PMID: 37525015 Free PMC article.
Honokiol is a FOXM1 antagonist.
Halasi M, Hitchinson B, Shah BN, Váraljai R, Khan I, Benevolenskaya EV, Gaponenko V, Arbiser JL, Gartel AL. Halasi M, et al. Among authors: varaljai r. Cell Death Dis. 2018 Jan 24;9(2):84. doi: 10.1038/s41419-017-0156-7. Cell Death Dis. 2018. PMID: 29367668 Free PMC article.
Persister state-directed transitioning and vulnerability in melanoma.
Chauvistré H, Shannan B, Daignault-Mill SM, Ju RJ, Picard D, Egetemaier S, Váraljai R, Gibhardt CS, Sechi A, Kaschani F, Keminer O, Stehbens SJ, Liu Q, Yin X, Jeyakumar K, Vogel FCE, Krepler C, Rebecca VW, Kubat L, Lueong SS, Forster J, Horn S, Remke M, Ehrmann M, Paschen A, Becker JC, Helfrich I, Rauh D, Kaiser M, Gul S, Herlyn M, Bogeski I, Rodríguez-López JN, Haass NK, Schadendorf D, Roesch A. Chauvistré H, et al. Among authors: varaljai r. Nat Commun. 2022 Jun 1;13(1):3055. doi: 10.1038/s41467-022-30641-9. Nat Commun. 2022. PMID: 35650266 Free PMC article.
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Váraljai R, et al. Nat Cancer. 2023 Sep;4(9):1395. doi: 10.1038/s43018-023-00632-w. Nat Cancer. 2023. PMID: 37580519 Free PMC article. No abstract available.
BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment.
Liu W, Stachura P, Xu HC, Váraljai R, Shinde P, Ganesh NU, Mack M, Van Lierop A, Huang A, Sundaram B, Lang KS, Picard D, Fischer U, Remke M, Homey B, Roesch A, Häussinger D, Lang PA, Borkhardt A, Pandyra AA. Liu W, et al. Among authors: varaljai r. Cancer Res. 2022 Jan 15;82(2):264-277. doi: 10.1158/0008-5472.CAN-21-1171. Epub 2021 Nov 22. Cancer Res. 2022. PMID: 34810198 Free PMC article.
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.
Shannan B, Matschke J, Chauvistré H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Livingstone E, Váraljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Marchetto A, Sannino G, Grünewald TGP, Schadendorf D, Jendrossek V, Roesch A. Shannan B, et al. Among authors: varaljai r. Eur J Cancer. 2019 Mar;109:137-153. doi: 10.1016/j.ejca.2018.12.024. Epub 2019 Feb 2. Eur J Cancer. 2019. PMID: 30721788
Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype.
Albrecht LJ, Höwner A, Griewank K, Lueong SS, von Neuhoff N, Horn PA, Sucker A, Paschen A, Livingstone E, Ugurel S, Zimmer L, Horn S, Siveke JT, Schadendorf D, Váraljai R, Roesch A. Albrecht LJ, et al. Among authors: varaljai r. Clin Transl Med. 2022 Nov;12(11):e1090. doi: 10.1002/ctm2.1090. Clin Transl Med. 2022. PMID: 36320118 Free PMC article.
The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition.
Hegedüs L, Livingstone E, Bánkfalvi Á, Viehof J, Enyedi Á, Bilecz Á, Győrffy B, Baranyi M, Tőkés AM, Gil J, Marko-Varga G, Griewank KG, Zimmer L, Váraljai R, Sucker A, Zaremba A, Schadendorf D, Aigner C, Hegedüs B. Hegedüs L, et al. Among authors: varaljai r. Int J Mol Sci. 2022 Mar 19;23(6):3324. doi: 10.3390/ijms23063324. Int J Mol Sci. 2022. PMID: 35328746 Free PMC article.
Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells.
Vogel FCE, Bordag N, Zügner E, Trajkovic-Arsic M, Chauvistré H, Shannan B, Váraljai R, Horn S, Magnes C, Thomas Siveke J, Schadendorf D, Roesch A. Vogel FCE, et al. Among authors: varaljai r. J Invest Dermatol. 2019 Dec;139(12):2506-2516.e10. doi: 10.1016/j.jid.2019.06.124. Epub 2019 Jun 21. J Invest Dermatol. 2019. PMID: 31229500 Free article.
Expression of polycomb targets predicts breast cancer prognosis.
Jene-Sanz A, Váraljai R, Vilkova AV, Khramtsova GF, Khramtsov AI, Olopade OI, Lopez-Bigas N, Benevolenskaya EV. Jene-Sanz A, et al. Among authors: varaljai r. Mol Cell Biol. 2013 Oct;33(19):3951-61. doi: 10.1128/MCB.00426-13. Epub 2013 Aug 5. Mol Cell Biol. 2013. PMID: 23918806 Free PMC article.
17 results